ZA201207727B - Morpholinylquinazolines - Google Patents
MorpholinylquinazolinesInfo
- Publication number
- ZA201207727B ZA201207727B ZA2012/07727A ZA201207727A ZA201207727B ZA 201207727 B ZA201207727 B ZA 201207727B ZA 2012/07727 A ZA2012/07727 A ZA 2012/07727A ZA 201207727 A ZA201207727 A ZA 201207727A ZA 201207727 B ZA201207727 B ZA 201207727B
- Authority
- ZA
- South Africa
- Prior art keywords
- morpholinylquinazolines
- Prior art date
Links
- LBZPDBABVQWCMA-UHFFFAOYSA-N 4-quinazolin-2-ylmorpholine Chemical class data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300' height='300' x='0' y='0'> </rect>
<path class='bond-0' d='M 74.0033,179.351 L 33.9487,172.372' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 74.0033,179.351 L 82.5087,169.173' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 82.5087,169.173 L 91.0142,158.995' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 33.9487,172.372 L 28.9426,158.705' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 28.9426,158.705 L 23.9365,145.037' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 29.0254,123.353 L 37.5309,113.174' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 37.5309,113.174 L 46.0364,102.996' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 46.0364,102.996 L 86.0909,109.975' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 86.0909,109.975 L 91.097,123.643' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 91.097,123.643 L 96.1032,137.31' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 110.014,149.884 L 125.071,152.508' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 125.071,152.508 L 140.129,155.131' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 140.129,155.131 L 145.135,168.799' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 145.135,168.799 L 150.141,182.467' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 149.266,156.435 L 152.771,166.002' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 152.771,166.002 L 156.275,175.57' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 140.129,155.131 L 148.634,144.953' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 148.634,144.953 L 157.14,134.774' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 164.052,195.041 L 179.109,197.664' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 179.109,197.664 L 194.167,200.288' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 194.167,200.288 L 220.238,169.089' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 191.838,190.394 L 210.088,168.554' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 220.238,169.089 L 260.293,176.068' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 220.238,169.089 L 206.255,130.911' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 260.293,176.068 L 286.364,144.869' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 257.963,166.174 L 276.213,144.334' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 286.364,144.869 L 272.38,106.691' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 272.38,106.691 L 232.326,99.7123' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 264.976,113.655 L 236.938,108.77' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 232.326,99.7123 L 206.255,130.911' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 206.255,130.911 L 191.197,128.288' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 191.197,128.288 L 176.139,125.664' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 200.341,138.135 L 189.801,136.299' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 189.801,136.299 L 179.261,134.462' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="end" x='24.9389' y='136.228' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='100.074' y='150.185' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='158.63' y='195.342' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='170.718' y='125.965' style='font-size:13px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85' height='85' x='0' y='0'> </rect>
<path class='bond-0' d='M 20.4676,50.3162 L 9.11881,48.3389' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 20.4676,50.3162 L 23.3588,46.8563' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15' d='M 23.3588,46.8563 L 26.25,43.3965' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 9.11881,48.3389 L 7.48943,43.8903' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1' d='M 7.48943,43.8903 L 5.86006,39.4418' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 6.76123,35.6019 L 9.65243,32.1421' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2' d='M 9.65243,32.1421 L 12.5436,28.6822' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3' d='M 12.5436,28.6822 L 23.8924,30.6595' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 23.8924,30.6595 L 25.5218,35.108' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-4' d='M 25.5218,35.108 L 27.1512,39.5566' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 29.5185,41.7665 L 34.3609,42.6102' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5' d='M 34.3609,42.6102 L 39.2032,43.4538' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 39.2032,43.4538 L 40.8326,47.9024' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 40.8326,47.9024 L 42.4619,52.3509' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 41.8554,43.996 L 42.996,47.11' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6' d='M 42.996,47.11 L 44.1365,50.2239' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 39.2032,43.4538 L 42.0944,39.994' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16' d='M 42.0944,39.994 L 44.9856,36.5341' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 44.8293,54.5608 L 49.6716,55.4045' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7' d='M 49.6716,55.4045 L 54.514,56.2482' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 54.514,56.2482 L 61.9008,47.4085' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8' d='M 53.854,53.4449 L 59.0248,47.2571' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9' d='M 61.9008,47.4085 L 73.2496,49.3858' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13' d='M 61.9008,47.4085 L 57.9388,36.5915' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 73.2496,49.3858 L 80.6364,40.5462' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10' d='M 72.5896,46.5825 L 77.7604,40.3947' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11' d='M 80.6364,40.5462 L 76.6744,29.7292' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 76.6744,29.7292 L 65.3256,27.7518' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12' d='M 74.5766,31.7023 L 66.6324,30.3182' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17' d='M 65.3256,27.7518 L 57.9388,36.5915' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 57.9388,36.5915 L 53.0965,35.7478' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 53.0965,35.7478 L 48.2541,34.9041' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 56.0906,38.6081 L 52.701,38.0176' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14' d='M 52.701,38.0176 L 49.3114,37.427' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text dominant-baseline="central" text-anchor="end" x='6.56603' y='38.0979' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#E84235' ><tspan>O</tspan></text>
<text dominant-baseline="central" text-anchor="middle" x='27.8544' y='42.0525' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='44.4453' y='54.8468' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
<text dominant-baseline="central" text-anchor="end" x='47.8701' y='35.1902' style='font-size:3px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;fill:#4284F4' ><tspan>N</tspan></text>
</svg>
 C1COCCN1C1=NC=C(C=CC=C2)C2=N1 LBZPDBABVQWCMA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010011493 | 2010-03-16 | ||
| PCT/EP2011/000767 WO2011113512A1 (en) | 2010-03-16 | 2011-02-17 | Morpholinylquinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201207727B true ZA201207727B (en) | 2013-06-26 |
Family
ID=43828057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/07727A ZA201207727B (en) | 2010-03-16 | 2012-10-15 | Morpholinylquinazolines |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9126952B2 (en) |
| EP (1) | EP2547664B1 (en) |
| JP (1) | JP2013522249A (en) |
| KR (1) | KR20130017086A (en) |
| CN (1) | CN102803227B (en) |
| AR (1) | AR080757A1 (en) |
| AU (1) | AU2011229542A1 (en) |
| BR (1) | BR112012022868A2 (en) |
| CA (1) | CA2793299A1 (en) |
| EA (1) | EA201201289A1 (en) |
| ES (1) | ES2586227T3 (en) |
| IL (1) | IL221901A (en) |
| MX (1) | MX2012010557A (en) |
| SG (1) | SG183855A1 (en) |
| WO (1) | WO2011113512A1 (en) |
| ZA (1) | ZA201207727B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118830A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Patent Gmbh | Morpholinylbenzotriazine |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| JP6360878B2 (en) | 2013-03-12 | 2018-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | DNA-PK inhibitor |
| UY35464A (en) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | KRAS G12C covalent inhibitors. |
| DE102013008118A1 (en) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| EP3636639A1 (en) * | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibitors of kras g12c |
| TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
| LT3424920T (en) | 2013-10-17 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2`-methyl-[4,5`-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
| TWI694837B (en) | 2014-09-18 | 2020-06-01 | 美商亞瑞克西斯製藥公司 | Combination therapies for treatment of cancer |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| KR20180005178A (en) | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds and methods for their use |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
| MX2018005967A (en) | 2015-11-16 | 2018-08-29 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof. |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN110036010A (en) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | The inhibitor of KRAS G12C mutain |
| CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
| WO2018218070A2 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
| JP2020521741A (en) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Compounds for the treatment of cancer and methods of their use |
| EP3551188A1 (en) * | 2017-10-31 | 2019-10-16 | Southern Research Institute | Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors |
| WO2020148403A1 (en) | 2019-01-17 | 2020-07-23 | Universite De Lille | 5-membered heteroaryl compounds containing a hydroxamate moiety and their use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69111077T2 (en) | 1990-11-06 | 1995-11-02 | Pfizer | CHINAZOLE DERIVATIVES TO IMPROVE ANTITUARY EFFECT. |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| JP2994165B2 (en) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | Quinazoline derivative, method for producing the same, and pharmaceutical preparation containing the quinazoline derivative for obtaining anticancer activity |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| TWI309647B (en) * | 2001-02-21 | 2009-05-11 | Mitsubishi Tanabe Pharma Corp | |
| CN1849122A (en) * | 2001-12-03 | 2006-10-18 | 先灵公司 | Method of treating cancer using fpt inhibitors and at least two antineoplastic agents |
| PE20060285A1 (en) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Substituted pyridones as inhibitors of pol (adp-ribose) polymerase (PARP) |
| ES2288359B1 (en) | 2005-07-08 | 2009-07-23 | Consejo Superior Investigaciones Cientificas | Coordinated control system for continuous extraction lines of virgin olive oil. |
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
| DE102006012251A1 (en) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments |
| EP1903038A1 (en) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators |
| JP5361857B2 (en) * | 2007-03-23 | 2013-12-04 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | Ion channel inhibitors |
| HUE030929T2 (en) * | 2007-07-20 | 2017-06-28 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| WO2009020140A1 (en) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | Adamantylurea derivative |
| CA2729045A1 (en) * | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| JP5793505B2 (en) * | 2009-12-23 | 2015-10-14 | ジャスコ ファーマシューティカルズ， エルエルシー | Aminopyrimidine kinase inhibitors |
-
2011
- 2011-02-17 BR BR112012022868A patent/BR112012022868A2/en not_active IP Right Cessation
- 2011-02-17 MX MX2012010557A patent/MX2012010557A/en not_active Application Discontinuation
- 2011-02-17 ES ES11704552.6T patent/ES2586227T3/en active Active
- 2011-02-17 AU AU2011229542A patent/AU2011229542A1/en not_active Abandoned
- 2011-02-17 US US13/581,699 patent/US9126952B2/en active Active
- 2011-02-17 CA CA 2793299 patent/CA2793299A1/en not_active Abandoned
- 2011-02-17 KR KR20127026875A patent/KR20130017086A/en not_active Application Discontinuation
- 2011-02-17 EA EA201201289A patent/EA201201289A1/en unknown
- 2011-02-17 WO PCT/EP2011/000767 patent/WO2011113512A1/en active Application Filing
- 2011-02-17 EP EP11704552.6A patent/EP2547664B1/en active Active
- 2011-02-17 SG SG2012064788A patent/SG183855A1/en unknown
- 2011-02-17 JP JP2012557426A patent/JP2013522249A/en active Pending
- 2011-02-17 CN CN201180014341.9A patent/CN102803227B/en not_active IP Right Cessation
- 2011-03-16 AR ARP110100836 patent/AR080757A1/en unknown
-
2012
- 2012-09-11 IL IL221901A patent/IL221901A/en not_active IP Right Cessation
- 2012-10-15 ZA ZA2012/07727A patent/ZA201207727B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG183855A1 (en) | 2012-10-30 |
| IL221901A (en) | 2016-04-21 |
| US9126952B2 (en) | 2015-09-08 |
| CA2793299A1 (en) | 2011-09-22 |
| US20130012489A1 (en) | 2013-01-10 |
| AU2011229542A1 (en) | 2012-11-08 |
| KR20130017086A (en) | 2013-02-19 |
| JP2013522249A (en) | 2013-06-13 |
| BR112012022868A2 (en) | 2018-06-05 |
| ES2586227T3 (en) | 2016-10-13 |
| CN102803227B (en) | 2016-01-20 |
| MX2012010557A (en) | 2012-10-05 |
| IL221901D0 (en) | 2012-12-02 |
| AR080757A1 (en) | 2012-05-09 |
| EP2547664A1 (en) | 2013-01-23 |
| EP2547664B1 (en) | 2016-05-04 |
| EA201201289A1 (en) | 2013-08-30 |
| WO2011113512A1 (en) | 2011-09-22 |
| CN102803227A (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181800T1 (en) | Well | |
| HRP20170903T1 (en) | Substituted pyrrolidine-2-carboxamides | |
| HRP20161308T1 (en) | 5-alkynyl-pyrimidines | |
| HRP20160360T1 (en) | Substituted imidazopyridazines | |
| HRP20160094T1 (en) | Triazine-oxadiazoles | |
| IL223783D0 (en) | Pro-neurogenic compounds | |
| HK1187908A1 (en) | Imidazotriazinone compounds | |
| ZA201207727B (en) | Morpholinylquinazolines | |
| GB201008134D0 (en) | Compounds | |
| GB201015949D0 (en) | Compounds | |
| EP2547244A4 (en) | Combination juicer-blender | |
| EP2566479A4 (en) | Azaindazoles | |
| EP2622917A4 (en) | Positioning | |
| GB201215746D0 (en) | Rotocraft | |
| GB201113558D0 (en) | Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung | |
| GB201010196D0 (en) | Methods | |
| HK1179966A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives -- | |
| GB201108084D0 (en) | Subbuffer objects | |
| EP2640189A4 (en) | 3-deutero-pomalidomide | |
| HK1181747A1 (en) | 1-hydroxyimino-3-phenyl-propanes 1--3-- | |
| HK1176934A1 (en) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes --[e] | |
| GB201205984D0 (en) | No details | |
| ZA201208514B (en) | Can manufacture | |
| ZA201207252B (en) | Can manufacture | |
| EP2622916A4 (en) | Positioning |